Genetic Foundations of Cystic Fibrosis

Genetics and Molecular Basis of Cystic Fibrosis Introduction Cystic fibrosis is a genetic disease caused by mutations in a single gene called the cystic fibrosis transmembrane conductance regulator (CFTR) gene. To have cystic fibrosis, a person must inherit two defective copies of this gene—one from each parent. Understanding the genetics of CF is essential for diagnosis, genetic counseling, and predicting disease severity. The CFTR Gene and Protein Function The CFTR gene is located on chromosome 7 (specifically at position 7q31.2) and encodes a protein that functions as a chloride channel. The CFTR protein sits embedded in the cell membrane of epithelial cells (cells that line organs like the lungs, pancreas, and intestines) and regulates the movement of chloride ions across the cell membrane. When the CFTR protein works normally, it allows chloride ions to pass through the cell membrane in a controlled way. This chloride movement is critical because it helps regulate the salt and water content of secretions like mucus, sweat, and digestive juices. In cystic fibrosis, defective CFTR protein leads to abnormally thick, sticky secretions that clog organs and cause the characteristic symptoms of the disease. CFTR Mutations and the ΔF508 Mutation More than 1,900 different mutations in the CFTR gene have been identified among cystic fibrosis patients worldwide. However, the distribution of these mutations is highly uneven. The vast majority of patients carry just a few common mutations, while most identified mutations occur in only a handful of individuals. The most common and clinically significant mutation is ΔF508 (deletion of phenylalanine at position 508). This single mutation accounts for approximately 70% of all CF cases worldwide and about 90% of cases in the United States. The ΔF508 mutation involves the loss of three DNA nucleotides that code for the amino acid phenylalanine at position 508 in the CFTR protein. This seemingly small deletion has major consequences: the protein misfolds during synthesis and is then destroyed by the cell before it can reach the cell membrane. Classification of CFTR Mutations CFTR mutations are classified into five categories based on how they affect the CFTR protein. Understanding these classes helps predict the severity of disease and guide treatment: Class I mutations prevent any CFTR protein from being made. These include nonsense mutations (which create premature stop signals) and frameshift mutations (which disrupt the reading frame of the genetic code). Because no functional protein is produced, these mutations typically cause severe disease. Class II mutations allow the protein to be made, but it misfolds during synthesis. The misfolded protein is recognized as defective by the cell's quality control systems and is degraded before it can reach the cell membrane. The ΔF508 mutation is the classic example of a Class II mutation. Patients with Class II mutations typically have severe disease. Class III mutations result in CFTR protein that reaches the cell membrane but cannot open properly to allow chloride to pass through. These "gating defects" usually cause moderate to severe disease. Class IV mutations produce CFTR protein that reaches the membrane and can open, but the chloride channel has reduced conductance—it doesn't transport as much chloride as normal. This typically results in milder disease. Class V mutations reduce the amount of normal CFTR protein that is made, usually through mutations that affect how the gene is transcribed. Because some normal protein is still produced, these mutations tend to cause milder disease. This classification system is important because mutations that preserve some CFTR protein function (Classes III, IV, and V) are generally associated with milder pulmonary disease compared to mutations that eliminate protein function entirely (Classes I and II). Autosomal Recessive Inheritance Cystic fibrosis follows an autosomal recessive inheritance pattern. This means: The CFTR gene is located on an autosome (not on a sex chromosome), so CF affects males and females equally A person needs to inherit two mutated copies of the CFTR gene (one from each parent) to have the disease A person with only one mutated copy is a carrier and is unaffected but can pass the mutation to offspring When both parents are carriers of CF mutations, their children face specific risks: Each child has a 25% chance of having cystic fibrosis (inheriting two mutated copies) Each child has a 50% chance of being a carrier (inheriting one mutated copy) Each child has a 25% chance of being unaffected (inheriting two normal copies) Carrier Screening and Genetic Counseling Carrier screening tests can identify individuals who carry one copy of a CFTR mutation. This is particularly important for: Family members of CF patients: They have an elevated risk of being carriers Population screening: Pan-ethnic carrier screening is recommended before pregnancy or as part of preconception counseling Reproductive planning: Couples who are both carriers face a 25% risk of having a child with CF for each pregnancy Genetic counseling accompanying carrier testing helps individuals understand their carrier status, assess reproductive risks, and make informed family planning decisions. Genotype-Phenotype Correlations An important principle in CF genetics is that the specific mutations a patient carries can influence the severity of their disease. This is called genotype-phenotype correlation. Pancreatic involvement is a key example of genotype-phenotype correlation. Certain CFTR mutations are strongly associated with pancreatic insufficiency (the inability of the pancreas to secrete digestive enzymes). Notably, mutations in Class I and II tend to cause severe pancreatic disease, while some Class IV and V mutations may be associated with pancreatic sufficiency. Similarly, pulmonary disease severity varies based on mutation type. Patients with Class I or II mutations (like ΔF508/ΔF508) typically develop more severe lung disease earlier in life, while some patients with Class III, IV, or V mutations may have relatively mild pulmonary involvement. This means that knowing a patient's genotype can sometimes help predict which organs will be most severely affected and how quickly the disease may progress. Diagnostic Testing: Sweat Chloride Test The primary diagnostic test for cystic fibrosis is the sweat chloride test (also called the sweat test). This test measures the concentration of chloride in sweat, which is abnormally high in patients with CF due to defective CFTR function in sweat gland cells. The sweat test is: Highly sensitive and specific: It accurately identifies CF patients while minimizing false positives Non-invasive: A small area of skin is stimulated to produce sweat, which is collected and analyzed Reliable: An elevated sweat chloride concentration is diagnostic for CF; a normal result essentially rules out the disease Molecular Diagnostic Testing While the sweat test confirms the diagnosis of CF, molecular genetic testing identifies the specific CFTR mutations a patient carries. This involves: DNA sequencing: Analyzing the CFTR gene to identify mutations Targeted mutation panels: Testing for the most common mutations (like ΔF508) Comprehensive mutation screening: Testing for less common mutations when initial panels are negative Molecular testing serves several purposes: Confirming the diagnosis when sweat test results are ambiguous or inconclusive Identifying specific mutations for genetic counseling and carrier screening in family members Predicting disease severity through genotype-phenotype correlations Guiding treatment decisions for newer therapies that target specific mutation classes <extrainfo> For reference, genetic testing typically identifies mutations when sweat chloride levels are elevated or intermediate, or when clinical symptoms suggest CF but sweat test results are borderline. </extrainfo>